GMAB
Price
$30.38
Change
-$0.32 (-1.04%)
Updated
Nov 28, 6:59 PM EST
77 days until earnings call
INCY
Price
$53.22
Change
+$0.52 (+0.99%)
Updated
Nov 29, 1:30 PM EST
78 days until earnings call
Ad is loading...

Compare predictions GMAB vs INCY

Header iconGMAB vs INCY Comparison
Open Charts GMAB vs INCYBanner chart's image
Genmab A/S ADS
Price$30.38
Change-$0.32 (-1.04%)
Volume$285.34K
CapitalizationN/A
Incyte
Price$53.22
Change+$0.52 (+0.99%)
Volume$800
CapitalizationN/A
View a ticker or compare two or three
GMAB vs INCY Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
GMAB vs. INCY commentary
Nov 29, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Hold and INCY is a Buy.

COMPARISON
Comparison
Nov 29, 2023
Stock price -- (GMAB: $30.38 vs. INCY: $52.70)
Brand notoriety: GMAB: Not notable vs. INCY: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 58% vs. INCY: 108%
Market capitalization -- GMAB: $20.04B vs. INCY: $11.85B
GMAB [@Biotechnology] is valued at $20.04B. INCY’s [@Biotechnology] market capitalization is $11.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • INCY’s FA Score: 1 green, 4 red.
According to our system of comparison, GMAB is a better buy in the long-term than INCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 4 TA indicator(s) are bullish while INCY’s TA Score has 4 bullish TA indicator(s).

  • GMAB’s TA Score: 4 bullish, 4 bearish.
  • INCY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both GMAB and INCY are a good buy in the short-term.

Price Growth

GMAB (@Biotechnology) experienced а -2.00% price change this week, while INCY (@Biotechnology) price change was -1.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.02%. For the same industry, the average monthly price growth was +37.81%, and the average quarterly price growth was +8.99%.

Reported Earning Dates

GMAB is expected to report earnings on Feb 14, 2024.

INCY is expected to report earnings on Feb 15, 2024.

Industries' Descriptions

@Biotechnology (+5.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for GMAB with price predictions.
OPEN
A.I.dvisor published
a Summary for INCY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
GMAB($20B) has a higher market cap than INCY($11.8B). GMAB has higher P/E ratio than INCY: GMAB (33.22) vs INCY (28.09). GMAB YTD gains are higher at: -28.315 vs. INCY (-34.387). GMAB has higher annual earnings (EBITDA): 5.4B vs. INCY (725M). GMAB has more cash in the bank: 27.5B vs. INCY (3.52B). INCY has less debt than GMAB: INCY (38.1M) vs GMAB (793M). GMAB has higher revenues than INCY: GMAB (17B) vs INCY (3.61B).
GMABINCYGMAB / INCY
Capitalization20B11.8B169%
EBITDA5.4B725M745%
Gain YTD-28.315-34.38782%
P/E Ratio33.2228.09118%
Revenue17B3.61B471%
Total Cash27.5B3.52B782%
Total Debt793M38.1M2,081%
FUNDAMENTALS RATINGS
GMAB vs INCY: Fundamental Ratings
GMAB
INCY
OUTLOOK RATING
1..100
2110
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
36100
SMR RATING
1..100
5974
PRICE GROWTH RATING
1..100
6262
P/E GROWTH RATING
1..100
6122
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCY's Valuation (68) in the Biotechnology industry is in the same range as GMAB (75) in the null industry. This means that INCY’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's Profit vs Risk Rating (36) in the null industry is somewhat better than the same rating for INCY (100) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than INCY’s over the last 12 months.

GMAB's SMR Rating (59) in the null industry is in the same range as INCY (74) in the Biotechnology industry. This means that GMAB’s stock grew similarly to INCY’s over the last 12 months.

GMAB's Price Growth Rating (62) in the null industry is in the same range as INCY (62) in the Biotechnology industry. This means that GMAB’s stock grew similarly to INCY’s over the last 12 months.

INCY's P/E Growth Rating (22) in the Biotechnology industry is somewhat better than the same rating for GMAB (61) in the null industry. This means that INCY’s stock grew somewhat faster than GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABINCY
RSI
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
63%
Momentum
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
64%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 6 days ago
70%
Bullish Trend 6 days ago
60%
Declines
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
60%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MSTR505.8710.49
+2.12%
MicroStrategy
MOBQ0.470.01
+1.30%
Mobiquity Technologies
NBN51.000.24
+0.47%
Northeast Bank
GNSS1.62-0.01
-0.70%
Genasys
TGLS34.08-0.98
-2.80%
Tecnoglass

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-1.04%
AXON - GMAB
47%
Loosely correlated
-0.48%
SRNEQ - GMAB
41%
Loosely correlated
+11.96%
INVA - GMAB
40%
Loosely correlated
-0.22%
MDGL - GMAB
38%
Loosely correlated
-3.22%
ADMA - GMAB
35%
Loosely correlated
-3.38%
More